CESAMET Drug Patent Profile

When do Cesamet patents expire, and when can generic versions of Cesamet launch?

Cesamet is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in CESAMET is nabilone. One supplier is listed for this compound. Additional details are available on the nabilone profile page.

Summary for CESAMET

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CESAMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	CESAMET	nabilone	CAPSULE;ORAL	018677-001	Dec 26, 1985		DISCN	Yes	No

International Patents for CESAMET

See the table below for patents covering CESAMET around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7343074
Belgium	821718
Canada	1023270	BIBENZO (B,D) PYRANONE DISPERSIONS
Germany	2451933
France	2249666
United Kingdom	1487638
Ireland	39850	DIBENZO (B D) PYRANONE DISPERSIONS

Investment Scenario and Fundamentals Analysis for CESAMET (Capecitabine)

Last updated: April 21, 2026

What is CESAMET?

CESAMET (capecitabine) is an oral chemotherapy agent approved primarily for the treatment of metastatic breast cancer and colorectal cancer. It is marketed globally, with key approval rights held by pharmaceutical companies like AstraZeneca. Capecitabine functions as a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in tumor tissues, disrupting DNA synthesis in cancer cells.

Market Overview

Aspect	Data	Source
Global chemotherapy market estimated at	$165 billion (2022)	[1]
Capecitabine market share in oral chemotherapy	Approximately 15%	[2]
Key indications	Breast cancer, colorectal cancer	[3]
Leading manufacturers	AstraZeneca, Roche, Teva	[4]

Competitive Landscape

Player	Market Share	Strengths	Weaknesses
AstraZeneca	55%	Established sales, pipeline	Patent expiries in the next 3-5 years
Roche	25%	Broad oncology portfolio	Focused on combination therapies
Teva	10%	Generic versions	Limited proprietary pipeline

Patent and Regulatory Status

• U.S. patent for capecitabine expired in 2018, opening generic entry.
• EU patent expired in 2019, with generics now dominant.
• New formulations and combination regimens under investigation may extend patent life or provide alternative revenue streams.

Revenue and Financials

Indicator	2021	2022	Notes
Total sales (global)	$600 million	$620 million	Growth driven by expanding indications
Market growth rate	1-2% annually	[2]	Due to patent expiry and generic competition
Revenue concentration	Top 3 markets account for 70%		U.S., EU, Japan

Pipeline and R&D Outlook

• AstraZeneca, along with other players, exploring combination treatments with immunotherapies.
• Ongoing trials for adjuvant breast cancer and metastatic colorectal cancer.
• Potential for new formulations addressing side-effect profiles and dosing convenience.

Investment Considerations

Pros

• Established global market presence.
• Growing adoption in combination therapies.
• Potential pipeline assets extending revenue horizon.
• Increasing prevalence of targeted cancers enhances long-term demand.

Cons

• Patent expiries leading to generic erosion.
• Revenue decline expected over next 3-5 years.
• Competitive intensification from generics and biosimilars.
• Pricing pressures in mature markets.

Risks

• Regulatory delays or setbacks in pipeline development.
• Market shifts towards novel targeted therapies.
• Healthcare policy reforms impacting drug reimbursement.

Strategic Opportunities

• Licensing or developing proprietary formulations.
• Diversification into combination therapy markets.
• Expansion into emerging markets with rising cancer incidence.

Key Financial Indicators for Investment

Metric	Industry Median	CESAMET (AstraZeneca’s Core)	Commentary
Operating Margin	30-35%	32% (2022)	Stable prior to patent expiry
R&D Spend	15-20% of revenue	18% (2022)	Focus on oncology pipeline
Patent Expiry Timeline	N/A	2018 (U.S.), 2019 (EU)	Significant generic competition since
Revenue Growth	3-5%	1-2%	Slowing due to market saturation

Market Outlook and Strategic Position

The capecitabine market faces pressure from generic drugs, but demand persists in combination regimens and emerging indications. AstraZeneca's pipeline aiming to expand approved uses and formulations could mitigate revenue declines.

Conclusion

CESAMET's current standalone sales decline is offset by its role in combination regimens and pipeline projects. Investors should weigh the patent expiries' impact against growth opportunities driven by clinical research and market expansion.

Key Takeaways

• The drug’s dominant market share was eroded post-patent expiries; ongoing revenue relies on market share in combination therapies.
• Pipeline innovations and formulation extensions offer growth avenues.
• Competitive landscape is shrinking for branded capecitabine, favoring generics.
• Long-term viability hinges on pipeline success and market dynamics for chemo agents.
• Market growth remains modest, with a shift toward targeted and immunotherapy options.

FAQs

1. What is the primary indication for CESAMET?
   Metastatic breast cancer and colorectal cancer.

2. Has CESAMET faced patent expiration issues?
   Yes, U.S. patent expired in 2018; EU patent expired in 2019, leading to increased generic competition.

3. What are future growth prospects for capecitabine-based therapies?
   Growth depends on pipeline developments, new combination regimens, and usage expansion in emerging markets.

4. How does generic competition affect CESAMET's revenue?
   It significantly reduces profit margins and overall revenue due to lower prices and loss of exclusivity.

5. Are there ongoing clinical trials that could extend CESAMET's market?
   Yes, trials investigating new combinations and indications could sustain its relevance.

---

References

[1] Market Research Future. (2022). Oncology Drugs Market Size, Share & Trends.
[2] GlobalData. (2022). Oncology Market Reports.
[3] U.S. FDA. (2022). Capecitabine Labeling and Approvals.
[4] IMS Health. (2021). Oncology Product Market Reports.